ArticleJournal of clinical laboratory analysis2026
The Ability of Serum Amyloid A to Discriminate Coronavirus Disease 2019 (COVID-19) Patients Who Stay Moderately Ill Versus Patients Who Become Severely Ill.
Article in Journal of clinical laboratory analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAs the disease course of coronavirus disease 2019 (COVID-19) can change rapidly, clinically relevant prognostic biomarkers could facilitate clinical-decision making. Prior research has shown that Serum Amyloid A (SAA) might serve as a prognostic biomarker in patients with COVID-19. The aim of this study was to determine the discriminative ability of SAA, C-reactive protein (CRP), ferritin, and procalcitonin (PCT) in patients with COVID-19 to differentiate between those who remain moderately ill from patients who become severely ill within 7 days of hospitalization.
methodsBlood samples and disease severity assessment were collected at day 1 (day of hospitalization), 3, 5, and 7 in a Dutch cohort of patients who were hospitalized for COVID-19. Blood was analyzed for concentrations of SAA, CRP, ferritin, and PCT.
results133 patients were included in this study. No differences in concentration of SAA, CRP, ferritin, and PCT at time of hospitalization were observed in patients who remained moderately ill compared to patients who progressed to severe COVID-19 within 7 days of hospitalization. ROC curve analysis revealed that SAA, CRP, ferritin, and PCT failed to discriminate patients who progressed to severe illness from those who remained moderately ill, with areas under the curve (AUC) of 0.461 for SAA, 0.500 for CRP, 0.528 for PCT, and 0.550 for ferritin.
conclusionOur study demonstrates that SAA, CRP, ferritin, and PCT levels at the time of hospitalization failed to discriminate between COVID-19 patients who remain moderately ill and those who progress to severe disease within 7 days.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.